Product Description
Secnidazole is structurally related to the commonly used 5-nitroimidazoles metronidazole and tinidazole. These drugs share a common spectrum of activity against anaerobic micro-organisms and they appear particularly effective in the treatment of amoebiasis, giardiasis, trichomoniasis and bacterial vaginosis. Secnidazole is rapidly and completely absorbed after oral administration and has a longer terminal elimination half-life (approximately 17 to 29 hours) than commonly used drugs in this class. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8706597/)
Mechanisms of Action: DNA Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Bangladesh | Brazil | Canada | Chile | China | Colombia | Dominican Republic | Ecuador | Egypt | France | India | Ireland | Jordan | Korea | Lebanon | Mexico | Morocco | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Vaginosis, Bacterial
Known Adverse Events: Abdominal Pain | Dysgeusia | Headache | Pain Unspecified | Pruritus | Candidiasis | Candidiasis, Vulvovaginal | Diarrhea
Company: Symbiomix
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Vaginal Diseases|Vaginosis, Bacterial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT05033743 | P3 |
Completed |
Vaginosis, Bacterial|Vaginal Diseases |
2022-10-07 |